The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II trial of chemoradiotherapy concurrent with S-1 plus cisplatin in patients with unresectable, locally advanced squamous cell carcinoma of the head and neck (SCCHN): Results of the Japan Clinical Oncology Group study, JCOG 0706.
Makoto Tahara
Consultant or Advisory Role - Merck Serono
Honoraria - Sanofi ; Taiho Pharmaceutical; Takeda
Research Funding - Eisai; Yakult Honsha
Naomi Kiyota
Research Funding - Health labour science research grant
Junki Mizusawa
No relevant relationships to disclose
Kenichi Nakamura
No relevant relationships to disclose
Ryuichi Hayashi
No relevant relationships to disclose
Tetsuo Akimoto
No relevant relationships to disclose
Yasuhisa Hasegawa
No relevant relationships to disclose
Shigemichi Iwae
No relevant relationships to disclose
Nobuya Monden
No relevant relationships to disclose
Kazuto Matsuura
No relevant relationships to disclose
Hirofumi Fujii
No relevant relationships to disclose
Yusuke Onozawa
No relevant relationships to disclose
Akihiro Homma
No relevant relationships to disclose
Akira Kubota
No relevant relationships to disclose
Haruhiko Fukuda
No relevant relationships to disclose
Masato Fujii
No relevant relationships to disclose